Biotech Values

[mcbio]

One should not completely discount ABBV/ENTA’s second-generation, 2-DAA, one-pill qD regimen of ABT-493 + ABT-530, which is just entering the clinic (#msg-89280030). Although the companies have refrained from calling this regimen pan-genotypic, they have said they expect it to have efficacy in multiple genotypes.

I think it's hard to envision this PI+NS5A combo having widespread efficacy across several genotypes. I'm sure there is at least strong potential in GT1b, if it pans out.